Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Concord Drugs's Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹31.9 Mil. Therefore, Concord Drugs's EV-to-EBIT ratio for today is 33.47.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Concord Drugs's Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹45.5 Mil. Therefore, Concord Drugs's EV-to-EBITDA ratio for today is 23.42.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Concord Drugs's Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹787.4 Mil. Therefore, Concord Drugs's EV-to-Revenue ratio for today is 1.35.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Concord Drugs's Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil. Therefore, Concord Drugs's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Concord Drugs (BOM:538965) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Concord Drugs's current Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹31.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Concord Drugs's current Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹45.5 Mil.
Concord Drugs's current Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹787.4 Mil.
Concord Drugs's current Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.
Concord Drugs's current Enterprise Value is ₹1,066.6 Mil.
Concord Drugs's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Drugs Enterprise Value Related Terms
Concord Drugs Enterprise Value Historical Data
* Premium members only.
The historical data trend for Concord Drugs's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Drugs Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Concord Drugs's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Concord Drugs's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of ₹1,066.6 Mil mean?
Concord Drugs (BOM:538965) has a Enterprise Value of ₹1,066.6 Mil as of Aug. 05, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Concord Drugs and its competitors.
Is Concord Drugs' Enterprise Value too high?
Concord Drugs' current Enterprise Value is ₹1,066.6 Mil. Overall, Concord Drugs has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' Enterprise Value compare to ZTS?
Concord Drugs' Enterprise Value of ₹1,066.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Concord Drugs and its competitors. Concord Drugs's current Enterprise Value is ₹1,066.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.93, compared to a current price of ₹71.23 — trading 16.9% above its estimated fair value. The current Enterprise Value is ₹1,066.6 Mil. Concord Drugs' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current Enterprise Value is ₹1,066.6 Mil as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Drugs (BOM:538965) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued.
The current stock price of ₹71.23 is trading 16.9% above its estimated GF Value™ of ₹60.93.
GuruFocus considers Concord Drugs to be Modestly Overvalued.
Key valuation signals for BOM:538965:
Enterprise Value: ₹1,066.6 Mil
GF Value™: ₹60.93 vs. price of ₹71.23 (16.9% above fair value)
No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score
Get the complete analysis for BOM:538965
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538965 has been successfully added to your 
